Back to Search Start Over

Imbalance of Chemokines and Cytokines in the Bone Marrow Microenvironment of Children with B-Cell Acute Lymphoblastic Leukemia.

Authors :
Magalhães-Gama F
Kerr MWA
de Araújo ND
Ibiapina HNS
Neves JCF
Hanna FSA
Xabregas LA
Carvalho MPSS
Alves EB
Tarragô AM
Martins-Filho OA
Teixeira-Carvalho A
Malheiro A
da Costa AG
Source :
Journal of oncology [J Oncol] 2021 Jul 22; Vol. 2021, pp. 5530650. Date of Electronic Publication: 2021 Jul 22 (Print Publication: 2021).
Publication Year :
2021

Abstract

In the hematopoietic microenvironment, leukemic cells secrete factors that imbalanced chemokine and cytokine production. However, the network of soluble immunological molecules in the bone marrow microenvironment of acute lymphoblastic leukemia (ALL) remains underexplored. Herein, we evaluated the levels of the immunological molecules (CXCL8, CCL2, CXCL9, CCL5, CXCL10, IL-6, TNF, IFN- γ , IL-17A, IL-4, IL-10, and IL-2) in the bone marrow plasma of 47 recently diagnosed B-cell acute lymphoblastic leukemia (B-ALL) patients during induction therapy using cytometric beads arrays. The results demonstrated that B-ALL patients showed high levels of CXCL9, CXCL10, IL-6, and IL-10 at the time of diagnosis, while at the end of induction therapy, a decrease in the levels of these immunological molecules and an increase in CCL5, IFN- γ , and IL-17A levels were observed. These findings indicate that B-ALL patients have an imbalance in chemokines and cytokines in the bone marrow microenvironment that contributes to suppressing the immune response. This immune imbalance may be associated with the presence of leukemic cells since, at the end of the induction therapy, with the elimination and reduction to residual cells, the proinflammatory profile is reestablished, characterized by an increase in the cytokines of the Th1 and Th17 profiles.<br />Competing Interests: FM-G, MWAK, FSAH, LAX, and JCFN have fellowship from FAPEAM and CAPES (Master's student). AT-C is level 2 research fellow from CNPq and research fellow from FAPEAM (PVN-II, PECTI-AM/SAÚDE Program #004/2020). OAM-F is level 1 research fellow from CNPq and a research fellow from FAPEAM (PVN-II, Pŕo-Estado Program-#002/2008, #007/2018 and #005/2019). AM is level 2 research fellow from CNPq. The authors declare no conflicts of interest.<br /> (Copyright © 2021 Fábio Magalhães-Gama et al.)

Details

Language :
English
ISSN :
1687-8450
Volume :
2021
Database :
MEDLINE
Journal :
Journal of oncology
Publication Type :
Academic Journal
Accession number :
34335758
Full Text :
https://doi.org/10.1155/2021/5530650